109181 ⎘
Structure or type of the nucleic acid; Chemical structure of the base; Modified C 5-Methylcytosine
Compositions and Methods for Treating and Preventing Prekallikrein-Associated Conditions
#2INTERFERING RNA FOR INHIBITING JAK1 GENE EXPRESSION AND USE THEREOF
#3Compositions for Modulating C9ORF72 Expression
#4SMALL RNA-BASED PROGNOSTIC SIGNATURES AND THERAPEUTIC COMPOSITIONS FOR IDIOPATHIC PULMONARY FIBROSIS
#5COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS
#6COMPOSITIONS AND METHODS FOR DELIVERING A MACROMOLECULE TO A CELL
#7Modulation of Apolipoprotein C-III (ApoCIII) Expression in Lipoprotein Lipase Deficient (LPLD) Populations
#8ANTISENSE OLIGONUCLEOTIDES FOR TARGETING PROGRANULIN
#9Compounds and Methods for Modulating UBE3A-ATS
#10RNAi AGENTS FOR MODULATING SNCA
#11RUNX1 MODULATORS
#12Compounds and Methods for Reducing ATXN3 Expression
#13POLYNUCLEOTIDE AGENTS TARGETING PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) AND METHODS OF USE THEREOF
#14ANTI-FIBROTIC MICRORNA COMPOSITION
#15COMPOSITIONS AND METHODS FOR TREATMENT OF NEUROINFLAMMATORY DISEASES
#16DOUBLE-STRANDED RNAI AGENTS AND COMPOSITIONS FOR REDUCING EXPRESSION OF ANGIOPOIETIN-LIKE 3 (ANGPTL3) AND METHODS OF USE THEREOF
#17COMPOUNDS AND METHODS FOR MODULATING SMN2
#18METHODS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE
#19OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF
#20METHODS FOR DECREASING OR INHIBITING HUMAN L1 RETROTRANSPOSON RNA AND COMPOSITIONS FOR USE THEREIN
#21COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION
#22RNAi AGENTS OF PRION EXPRESSION
#23EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING CEBP/BETA
#24Compositions and Methods for Modulating Complement Factor B Expression
#25MRNA FOR SARS-COV-2 S PROTEIN AND USE THEREOF
#26ANTI-C9ORF72 OLIGONUCLEOTIDES AND RELATED METHODS
#27OLIGONUCLEOTIDES FOR MODULATING RTEL1 EXPRESSION
#28COMPOUNDS AND METHODS FOR REDUCING PRION EXPRESSION
#29OLIGONUCLEOTIDES FOR INDUCING PATERNAL UBE3A EXPRESSION
#30Methods and Compositions for Adar-Mediated Editing
#31ADVANCED RNA TARGETING (ARNATAR)
#32Selective Antisense Compounds and Uses Thereof
#33NUCLEOTIDE ANALOGUES, AND PREPARATION AND APPLICATION THEREOF
#34MUSCLE TARGETING COMPLEXES AND FORMULATIONS FOR TREATING MYOTONIC DYSTROPHY
#35ANTISENSE OLIGONUCLEOTIDES FOR TARGETING PROGRANULIN
#36Antisense Compounds Targeted to CLN3 and Uses Thereof
#37RNAI AGENT INHIBITING PCSK9 GENE EXPRESSION AND APPLICATION THEREOF
#38CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE
#39Antisense Oligonucleotide for Targeting Progranulin
#40COMPOUNDS AND METHODS FOR REDUCING PLN EXPRESSION
#41ANTISENSE OLIGOMERS AGAINST MONOAMINE OXIDASE B AND USE THEREOF
#42METHODS AND COMPOSITIONS FOR MODULATING APOLIPOPROTEIN (A) EXPRESSION
#43Conjugated Antisense Compounds and Their Use
#44OLIGONUCLEOTIDES FOR THE TREATMENT OF NUCLEOTIDE REPEAT EXPANSION DISORDERS ASSOCIATED WITH MSH3 ACTIVITY
#45APTAMER, CONJUGATE, COMPOSITION, METHOD FOR PREPARING SAME, AND USE THEREOF
#46Compounds and Methods for Reducing KCNT1 Expression
#47MODULATION OF ABCB11 GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS
#48METHODS FOR REDUCING TAU EXPRESSION
#49PRODUCTS AND COMPOSITIONS
#50Compounds and Methods for Reducing LRRK2 Expression
#51OLIGONUCLEOTIDE-BASED DELIVERY VEHICLE FOR OLIGONUCLEOTIDES AGENTS AND METHODS OF USE THEREOF
#52COMPOUNDS AND METHODS FOR MODULATING ATXN1
#53TARGETED TREATMENT OF SPLICEOPATHY-INDUCED NEUROLOGICAL DISORDERS
#54MODULATION OF SYNGAP1 GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS
#55COMPOSITIONS FOR THE SILENCING OF snoRNAS AND METHODS OF USING SAME
#56MODULATORS OF DIACYGLYCEROL ACYLTRANSFERASE 2 (DGAT2)
#57MAPT ANTISENSE OLIGONUCLEOTIDE
#58Compounds and Methods for Modulating UBE3A-ATS
#59ENHANCED HAMMERHEAD RIBOZYMES AND METHODS OF USE
#60TARGETED AUGMENTATION OF NUCLEAR GENE OUTPUT
#61ANTI-CANCER AGENTS
#62Selective Antisense Compounds and Uses Thereof
#63PHARMACEUTICAL COMBINATIONS FOR TREATMENT OF HBV
#64Linkage Modified Oligomeric Compounds
#65REVERSIR TM COMPOUNDS
#66MODULATION OF GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS
#67TRANSLATION ENHANCING NUCLEIC ACID COMPOUNDS: ASO COUPLED TRANSLATION – UPREGULATION 1 (ACT-UP1) AND USES THEREOF
#68UNIVERSAL NON-TARGETING SIRNA COMPOSITIONS AND METHODS OF USE THEREOF
#69METHODS OF MODULATING PROGRANULIN EXPRESSION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS
#70SYF2 ANTISENSE OLIGONUCLEOTIDES
#71Selective Reduction of Allelic Variants
#72IMMUNOSTIMULATORY COMPOSITIONS
#73PHYTOECDYSONES AND/OR 20-HYDROXYECDYSONE DERIVATIVES IN COMBINATION WITH AN ACTIVE INGREDIENT FOR RESTORING SMN EXPRESSION, FOR USE IN THE TREATMENT OF SPINAL MUSCULAR ATROPHY
#74RNAi Agents of Modulating PLP1
#75METHODS FOR THE TREATMENT OF NUCLEOTIDE REPEAT EXPANSION DISORDERS ASSOCIATED WITH MSH3 ACTIVITY
#76COMPOUNDS AND METHODS FOR REDUCING IFNAR1 EXPRESSION
#77Methods and Compositions for Treatment of Polycystic Kidney Disease
#78ANTISENSE OLIGONUCLEOTIDES TARGETING ALPHA-SYNUCLEIN AND USES THEREOF
#79ANTISENSE OLIGONUCLEOTIDES FOR TARGETING PROGRANULIN
#80METHODS OF USING OLIGOMERIC COMPOUNDS TO TREAT SCN2A-RELATED DISORDERS
#81COMPOUNDS AND METHODS FOR MODULATING SMN2
#82COMPOUNDS AND METHODS FOR REDUCING DMPK EXPRESSION
#83THERAPEUTIC COMPOSITIONS FOR TREATING PAIN VIA MULTIPLE TARGETS
#84ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF
#85MULTIPLE EXON SKIPPING COMPOSITIONS FOR DMD
#86ANTISENSE OLIGONUCLEOTIDES TARGETING ADENOSINE KINASE
#87OLIGONUCLEOTIDE AGONISTS TARGETING PROGRANULIN
#88MODULATION OF ALPHA SYNUCLEIN EXPRESSION
#89COMPOSITIONS AND METHODS FOR PREPARING CAPPED CIRCULAR RNA MOLECULES
#90Oligonucleotides Comprising Modified Nucleosides
#91COMBINATIONS WITH MODULATORS OF PNPLA3 EXPRESSION
#92OLIGONUCLEOTIDES FOR INDUCING PATERNAL UBE3A EXPRESSION
#93COMPOSITIONS AND METHODS FOR TREATMENT OF PAIN
#94COMPOUNDS AND METHODS FOR MODULATING PROGRANULIN EXPRESSION
#95COMPOUNDS AND METHODS FOR THE MODULATION OF PROTEINS
#96DEGRADATION OF RNA BY THE LYSOSOMAL PATHWAY
#97MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FRIEDREICH'S ATAXIA
#98METHODS OF TREATMENT OF SCN2A-RELATED DISORDERS
#99PIKFYVE ANTISENSE OLIGONUCLEOTIDES
#100COMBINATION THERAPY FOR TREATING HEPATITIS B VIRUS INFECTIONS
#101MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF
#102Application of PRDX5 and GPX4 Genes in Preparation of Drugs for Castration-resistant Prostate Cancer
#103COMPOUNDS AND METHODS FOR MODULATION OF DYSTROPHIA MYOTONICA-PROTEIN KINASE (DMPK) EXPRESSION
#104MODULATORS OF APOL1 EXPRESSION
#105INHIBIN SUBUNIT BETA E (INHBE) MODULATOR COMPOSITIONS AND METHODS OF USE THEREOF
#106Antisense Oligonucleotide for Targeting Progranulin
#107TREATMENT OF NEUROLOGICAL DISEASES USING MODULATORS OF UNC13A GENE TRANSCRIPTS
#108Methods and Compositions for ADAR-Mediated Editing
#109Conjugates of guide RNA-Cas protein complex for genome and epigenome editing
#110METHODS AND COMPOSITIONS FOR INHIBITING PMP22 EXPRESSION
#111RNA MODULATING OLIGONUCLEOTIDES WITH IMPROVED CHARACTERISTICS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
#112PHARMACEUTICAL COMBINATIONS FOR TREATMENT OF HBV
#113OLIGONUCLEOTIDES FOR TARGETING COMPLEMENT C5
#114COMBINATION OF OLIGONUCLEOTIDES FOR MODULATING RTEL1 AND FUBP1
#115COMPOUNDS AND METHODS FOR REDUCING PLN EXPRESSION
#116COMPOSITIONS AND METHODS FOR MODULATING PKK EXPRESSION
#117Nucleic Acid Sponges
#118COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION
#119THERAPEUTIC USES AND METHODS
#120COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES AND PROCESSES RELATED TO ALTERATION OF THEIR PHYSIOCHEMICAL CHARACTERISTICS
#121ANTISENSE OLIGONUCLEOTIDES FOR MODULATING TMEM106B EXPRESSION
#122COMPOUNDS AND METHODS FOR MODULATING HUNTINGTIN
#123POLYNUCLEOTIDES ENCODING URIDINE DIPHOSPHATE GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1 FOR THE TREATMENT OF CRIGLER-NAJJAR SYNDROME
#124IL-34 ANTISENSE AGENTS AND METHODS OF USING SAME
#125OLIGONUCLEOTIDES COMPRISING SEGMENTED GAP STRUCTURES
#126DYSTROPHIN EXON SKIPPING OLIGONUCLEOTIDES
#127Selective Antisense Compounds and Uses Thereof
#128Compounds and methods for reducing LRRK2 expression
#129MODULATION OF GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS
#130COMPOUNDS AND METHODS FOR MODULATING SCN1A EXPRESSION
#131SNRNA TARGETING USH2A PRE-MRNA AND APPLICATION THEREOF
#132Compositions and methods for modulating apolipoprotein (a) expression
#133Modulation of gene transcription using antisense oligonucleotides targeting regulatory RNAs
#134COMPOUNDS AND METHODS FOR REDUCING DUX4 EXPRESSION
#135ANTISENSE OLIGONUCLEOTIDES TARGETING UNC13A
#136MODULATORS OF ENaC EXPRESSION
#137ALLELE-SELECTIVE COMPOUNDS AND METHODS FOR MODULATING HUNTINGTIN EXPRESSION
#138MODULATION OF PREKALLIKREIN (PKK) EXPRESSION
#139Multi-Valent Oligonucleotide Agent and Methods of Use Thereof
#140COMPOUNDS AND METHODS FOR INCREASING STMN2 EXPRESSION
#141COMPOSITIONS FOR MODULATING ATAXIN 2 EXPRESSION
#142COMPOUNDS AND METHODS FOR REDUCING TAU EXPRESSION
#143COMPOUNDS FOR MODULATING UNC13A EXPRESSION
#144MICRORNA-134 INHIBITORS
#145COMPOUNDS AND METHODS FOR REDUCING ATXN3 EXPRESSION
#146ANTISENSE-OLIGONUCLEOTIDES FOR PREVENTION OF KIDNEY DYSFUNCTION PROMOTED BY ENDOTHELIAL DYSFUNCTION BY EPHRIN-B2 SUPPRESSION
#147Selective Antisense Compounds and Uses Thereof
#148ANTISENSE OLIGONUCLEOTIDES TARGETING SCN2A FOR THE TREATMENT OF SCN1A ENCEPHALOPATHIES
#149MODULATION OF NOX4 EXPRESSION
#150Oligonucleotides for Modulating Apolipoprotein E4 Expression
#151Methods and Compositions for Treatment of Polycystic Kidney Disease
#152INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN, ACID LABILE SUBUNIT (IGFALS) AND INSULIN-LIKE GROWTH FACTOR 1 (IGF-1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#153Compounds and Methods for Modulating Splicing of Pre-MRNA
#154Conjugated antisense compounds and their use
#155COMPOUNDS FOR REDUCING PTBP1 EXPRESSION
#156Asymmetric Short Duplex DNA as a Novel Gene Silencing Technology and Use Thereof
#157METHODS FOR THE TREATMENT OF NUCLEOTIDE REPEAT EXPANSION DISORDERS ASSOCIATED WITH MSH3 ACTIVITY
#158Short Duplex DNA as a Novel Gene Silencing Technology and Use Thereof
#159EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING STAT6
#160Modulators of Complement Factor B
#161METHOD FOR DESIGNING OLIGONUCLEOTIDE HAVING REDUCED CENTRAL TOXICITY
#162CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE
#163COMPOUNDS AND METHODS FOR REDUCING KCNT1 EXPRESSION
#164RNA Containing Modified Nucleosides and Methods of Use Thereof
#165MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FRIEDREICH'S ATAXIA
#166THERAPEUTIC COMPOSITIONS FOR TREATING PAIN VIA MULTIPLE TARGETS
#167COMPOUNDS AND METHODS FOR MODULATING PLP1
#168Compositions for Modulating C9ORF72 Expression
#169COMPOUNDS AND METHODS FOR REDUCING NLRP3 EXPRESSION
#170COMPOUNDS AND METHODS FOR REDUCING PLN EXPRESSION
#171METHODS FOR MODULATING FMR1 EXPRESSION
#172OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF
#173NUCLEIC ACID DELIVERY TO THE CENTRAL NERVOUS SYSTEM
#174MODULATION OF GYS1 EXPRESSION
#175METHODS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE
#176Selective Antisense Compounds and Uses Thereof
#177MODULATION OF TRANSTHYRETIN EXPRESSION
#178RNA Containing Modified Nucleosides and Methods of Use Thereof
#179MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY
#180POLYNUCLEOTIDE AGENTS TARGETING PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) AND METHODS OF USE THEREOF
#181REGULATORY SYSTEM FOR EXPRESSION OF A GENE OF INTEREST IN A TARGET CELL AND METHOD OF USE THEREOF
#182COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS
#183IL-34 antisense agents and methods of using same
#184OLIGONUCLEOTIDES FOR INDUCING PATERNAL UBE3A EXPRESSION
#185COMPOUNDS AND METHODS FOR REDUCING ATXN3 EXPRESSION
#186Target Ligand
#187METHODS AND COMPOSITIONS FOR MODULATING APOLIPOPROTEIN (A) EXPRESSION
#188Compounds and methods for modulating ATXN1
#189ANTISENSE COMPOUNDS
#190OLIGONUCLEOTIDE AND USE THEREOF AGAINST HEPATITIS B VIRUS AND HEPATITIS D VIRUS
#191Oligomers and oligomer conjugates
#192MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF
#193RNA PREPARATIONS COMPRISING PURIFIED MODIFIED RNA FOR REPROGRAMMING CELLS
#194MODIFIED OLIGONUCLEOTIDES FOR USE IN TREATMENT OF TAUOPATHIES
#195COMPOUNDS FOR MODULATING CHMP7
#196UMLILO ANTISENSE TRANSCRIPTION INHIBITORS
#197COMPOUNDS AND METHODS FOR MODULATING PMP22
#198COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION
#199COMPOUNDS AND METHODS FOR REDUCING APOE EXPRESSION
#200ACTIVATORS OF TYPE III CAS PROTEINS
#201DYSTROPHIN EXON SKIPPING OLIGONUCLEOTIDES
#202OLIGOMERS HAVING BICYCLIC SCAFFOLD MOIETIES
#203COMPLEMENT COMPONENT C1R INHIBITORS FOR TREATING A NEUROLOGICAL DISEASE, AND RELATED COMPOSITIONS, SYSTEMS AND METHODS OF USING SAME
#204Compositions for modulating tau expression
#205Modulators of PCSK9 Expression
#206Oligonucleotides comprising modified nucleosides
#207COMPLEMENT COMPONENT 4 INHIBITORS FOR TREATING NEUROLOGICAL DISEASES, AND RELATED COMPOSITONS, SYSTEMS AND METHODS OF USING SAME
#208POLYNUCLEOTIDE AGENTS TARGETING ANGIOTENSINOGEN (AGT) AND METHODS OF USE THEREOF
#209Oligonucleotides for inducing paternal UBE3A expression
#210ANTI-C9ORF72 OLIGONUCLEOTIDES AND RELATED METHODS
#211Oligonucleotide Agonists Targeting Progranulin
#212COMPOSITIONS FOR FLCN GENE MODULATION AND METHODS THEREOF
#213THERAPEUTICS FOR SYNGAP HAPLOINSUFFICIENCY
#214Modulators of APOL1 expression
#215MODULATION OF FACTOR 11 EXPRESSION
#216SIRNA OF ANGPTL3 AND USE THEREOF
#217COMPOUNDS AND METHODS FOR REDUCING MSH3 EXPRESSION
#218Compounds and Methods for Reducing ATXN3 Expression
#219COMPOSITIONS OF SMAD7 ANTISENSE OLIGONUCLEOTIDES (ASO) AND METHODS OF USING THE SAME
#220METHODS AND COMPOSITIONS FOR MODULATING ALPHA-1-ANTITRYPSIN EXPRESSION
#221USE OF SBDS INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION
#222Compositions and Methods for Modulation of SMN2 Splicing in a Subject
#223Immunostimulatory compositions
#224Modulation of Dystrophia Myotonica-Protein Kinase (DMPK) Expression
#225METHODS AND COMPOSITIONS FOR TREATING ATAXIA TELANGIECTASIA
#226Compositions for FNIP1/FNIP2 Gene Modulation and Methods Thereof
#227COMPOUNDS AND METHODS FOR REDUCING PSD3 EXPRESSION
#228ANTISENSE OLIGONUCLEOTIDE OF CALM2
#229PREVENTION OR TREATMENT OF ANEURYSMS USING MIR-33B INHIBITOR
#230COMPOSITIONS AND METHODS OF INHIBITING SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
#231COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION
#232COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING PREKALLIKREIN-ASSOCIATED CONDITIONS
#233MODULATORS OF GROWTH HORMONE RECEPTOR
#234EXTRACELLULAR VESICLE-NLRP3 ANTAGONIST
#235COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION
#236USE OF SCAMP3 INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION
#237COMPOUNDS AND METHODS FOR MODULATING SPLICING OF PRE-MRNA
#238ANTISENSE OLIGOMERS FOR TREATMENT OF CONDITIONS AND DISEASES
#239Compounds and methods for reducing LRRK2 expression
#240Selective Antisense Compounds and Uses Thereof
#241Compositions for Modulating C9ORF72 Expression
#242METHODS FOR REDUCING HTT EXPRESSION
#243EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
#244COMPOSITIONS AND METHODS TO TREAT NEUROLOGICAL DISEASES
#245Nucleic Acid Compounds for Binding to Complement Component 3 Protein
#246Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity
#247Compositions and methods for modulating complement factor B expression
#248COMPOUNDS AND METHODS FOR REDUCING APP EXPRESSION
#249Antisense Oligonucleotides Targeting ATXN3
#250RNA containing modified nucleosides and methods of use thereof
#251Modulators of diacyglycerol acyltransferase 2 (DGAT2)
#252COMPOUNDS AND METHODS FOR MODULATING SCN1A EXPRESSION
#253METHODS FOR THE TREATMENT OF TRINUCLEOTIDE REPEAT EXAPNSION DISORDERS ASSOCIATED WITH OGG1 ACTIVITY
#254COMPOSITIONS AND METHODS FOR MODULATING ATAXIN 3 EXPRESSION
#255Modulation of huntingtin expression
#256IDENTIFYING NON-PRODUCTIVE SPLICE SITES
#257EXTRACELLULAR VESICLES WITH ANTISENSE OLIGONUCLEOTIDES TARGETING KRAS
#258Compounds and methods for modulating factor XII
#259IL-34 ANTISENSE AGENTS AND METHODS OF USING SAME
#260Selective antisense compounds and uses thereof
#261PIKFYVE antisense oligonucleotides
#262COMPOSITIONS AND METHODS FOR DECREASING TAU EXPRESSION
#263Compounds and methods for modulating UBE3A-ATS
#264Modulation of Angiopoietin-Like 3 Expression
#265Selective reduction of allelic variants
#266RNA MODULATING OLIGONUCLEOTIDES WITH IMPROVED CHARACTERISTICS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
#267COMPOUNDS AND METHODS FOR REDUCING APP EXPRESSION
#268ANTISENSE OLIGONUCLEOTIDE CAPABLE OF ALTERING SPLICING OF DUX4 pre-mRNA
#269ANTISENSE OLIGONUCLEOTIDES AND THEIR USE FOR TREATING PENDRED SYNDROME
#270COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION
#271COMPOUNDS AND METHODS FOR MODULATING ANGIOTENSINOGEN EXPRESSION
#272Compounds and methods for modulating ATXN1
#273MOLECULAR TARGETED NUCLEIC ACID MEDICINE FOR GASTRIC CANCER
#274OLIGONUCLEOTIDE THERAPY FOR STARGARDT DISEASE
#275COMPOSITIONS AND METHODS FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA
#276COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION
#277UBE3A ANTISENSE THERAPEUTICS
#278EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
#279REVERSIR™ compounds
#280Methods and compositions for inhibiting PMP22 expression
#281ANGIOTENSIN II TYPE 1 RECEPTOR TARGETED OLIGONUCLEOTIDES AND USES THEREOF
#282Modulators of Complement Factor B
#283COMPOUNDS AND METHODS FOR REDUCING FUS EXPRESSION
#284COMPOSITIONS AND METHODS FOR MODULATING TAU EXPRESSION
#285COMPOUND, METHOD AND PHARMACEUTICAL COMPOSITION FOR MODULATING EXPRESSION OF DUX4
#286METHODS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE
#287MODULATION OF TRANSTHYRETIN EXPRESSION
#288MODULATION OF APOLIPOPROTEIN C-III (APOCIII) EXPRESSION IN LIPOPROTEIN LIPASE DEFICIENT (LPLD) POPULATIONS
#289Antisense oligonucleotide for targeting progranulin
#290TAU-TARGETING OLIGONUCLEOTIDE GAPMERS
#291Compositions for modulating Ataxin 2 expression
#292COMPOUNDS AND METHODS FOR REDUCING KCNT1 EXPRESSION
#293Antisense Oligonucleotides Targeting ATXN3
#294Modulation of prekallikrein (PKK) expression
#295NUCLEIC ACID COMPLEX FOR MODULATING IHH EXPRESSION
#296ANTISENSE OLIGONUCLEOTIDE-BASED PROGRANULIN AUGMENTATION THERAPY IN NEURODEGENERATIVE DISEASES
#297Compounds and methods for modulating angiotensinogen expression
#298Oligonucleotides for inducing paternal UBE3A expression
#299FRAGILE X MENTAL RETARDATION PROTEIN INTERFERING OLIGONUCLEOTIDES AND METHODS OF USING SAME
#300OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF